GeneDx Holdings And 2 Top AI Healthcare Stocks To Watch

Heavy spending on artificial intelligence by giants like Amazon and Intel is starting to pinch cash flows and spook parts of the market. That short term worry creates an opening for investors looking at AI in healthcare, where the story is about using algorithms to cut costs and improve outcomes. This article walks through three AI driven healthcare stocks from our screener that could benefit if this spending shift continues.

The three stocks highlighted below are just a first sample from this theme, and the full screen surfaced 33 more AI in healthcare companies with equally compelling narratives that are not covered here. If you want to go further than this shortlist, use the Transformative Artificial intelligence (AI) Healthcare Stocks screener to identify, analyze, and focus on the highest conviction ideas for your watchlist.

GeneDx Holdings (WGS)

GeneDx Holdings plugs directly into the AI healthcare theme by using machine learning to interpret complex genomes for rare disease and cancer, turning raw sequencing into clinical answers at scale while still running a sizeable genetic testing service in the United States.

GeneDx focuses on genomic testing and data services, centered on whole exome and genome sequencing supported by an AI driven interpretation platform for rare disease, hereditary risk, and cancer. Segment Adjustment contributes about $423 million and Fabric Genomics and Legacy Sema4 about $31 million in revenue, all from the United States, with the business valued at roughly $2.1b in market cap.

"While management is prioritizing payer coverage and AI driven revenue cycle tools to close the gap between current collection rates around the low 30% range and the longer term ~70% target, the persistence of roughly 32% outpatient genome collections through Q2 2026 suggests that any improvement in net collections and earnings could arrive more slowly than the volume growth in tests."

What happens to GeneDx’s earnings profile if a single pressure point tied to how those high value tests translate into cash collections breaks its way?

If that cash conversion gap intrigues you, read the full narrative for GeneDx Holdings to see how payer behavior, AI tooling, and test mix could be quietly rewiring GeneDx’s earnings story.

Pfizer (PFE)

Pfizer uses its huge global drug portfolio as the testing ground for AI driven R&D, where biomolecular foundation models and data heavy discovery partnerships are starting to reshape how quickly it can design and prioritize new therapies across vaccines, oncology, and specialty medicines.

Pfizer develops and sells a wide range of branded treatments across internal medicine, vaccines, oncology, immunology, rare disease, and hospital products. The Global Biopharmaceuticals Business generates about US$62.3b of its revenue and total market value is around US$167.9b.

"Broader roll out of AI and advanced analytics across R&D, manufacturing and commercial operations, which has already tripled international salesforce productivity and shortened clinical reporting timelines, is designed to keep Pfizer’s cost structure efficient and can influence both margins and earnings as these tools are applied more widely."

What happens to Pfizer’s earnings power if one crucial assumption about how quickly these AI platforms feed into the late stage pipeline breaks its way?

If that late stage acceleration is what you care about, read the full narrative for Pfizer to see how AI productivity gains could be masking a very different earnings arc.

Insmed (INSM)

Insmed focuses on serious respiratory and rare diseases through drugs like ARIKAYCE, BRINSUPRI and TPIP, while also running an AI driven pre clinical effort in protein engineering that aims to speed up how future biologic therapies are designed and manufactured.

Insmed, now valued at about US$24.4b, gives the AI healthcare theme a drug developer that already has meaningful respiratory franchises in market, while quietly testing machine learning in the background on how proteins get built and scaled for future treatments.

"Although BRINSUPRI is tracking toward at least US$1b in 2026 revenue and shows strong refill and continuation behavior, the reliance on a relatively new oral therapy in a historically untreated bronchiectasis population could expose the company to slower than expected long term adoption if physicians remain cautious."

What happens to Insmed’s earnings power if a single pressure point around how quickly everyday pulmonologists change prescribing habits breaks its way?

When that adoption curve matters to you, read the full narrative for Insmed to see how Insmed’s AI work could be quietly accelerating the long term story.

Seeking Alternatives Before The Crowd

Fresh themes often move first, and slower portfolios can get caught chasing momentum while prices are already rising. Scan under the radar for now and consider acting earlier in the process.

• Spot cash-rich compounders early by running the 30 high quality undervalued stocks before additional buyers focus on those balance sheet and cash flow stories.
• Track where automation momentum is building by checking the curated 95 robotics and automation stocks while these operators are still viewed as niche suppliers.
• Monitor capital rotating into resilient payers by scanning the 7 dividend fortresses before yields change and total return calculations look different.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com